Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.50 |
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.41 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.41 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KDM5C | P41229 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.39 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.39 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17164992 | 1.00 | GNPAT (0.50) | GNPATNOD1FOLH1RIMKLANAALAD2 | |
| SCHEMBL17164986 | 0.87 | GNPAT (0.43) | GNPATNOD1FOLH1RIMKLANAALAD2 | |
| SCHEMBL17164985 | 0.87 | GNPAT (0.43) | GNPATNOD1FOLH1RIMKLANAALAD2 | |
| SCHEMBL29474806 | 0.82 | NOD1 (0.59) | NOD1FOLH1GLO1 | |
| SCHEMBL17164973 | 0.81 | NOD1 (0.45) | GNPATNOD1FOLH1RIMKLANAALAD2 | |
| SCHEMBL17164972 | 0.81 | NOD1 (0.45) | GNPATNOD1FOLH1RIMKLANAALAD2 | |
| SCHEMBL18734973 | 0.80 | NOD1 (0.41) | GNPATNOD1FOLH1RIMKLANAALAD2 | |
| SCHEMBL18737721 | 0.79 | NOD1 (0.38) | NOD1FOLH1EPHX2GLO1 | |
| SCHEMBL6661430 | 0.79 | GLO1 (0.54) | NOD1EPHX2GLO1 | |
| SCHEMBL12655871 | 0.77 | GNPAT (0.56) | GNPATNOD1FOLH1RIMKLANAALAD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3391941-B1 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | Abliva Ab (SE) | 2023-06-07 | — | — | EP | disclosed |
| EP-3391941-B1 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | Abliva Ab (SE) | 2023-06-07 | — | — | EP | disclosed |
| US-20210401792-A1 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | Abliva Ab (SE) | 2021-12-30 | — | — | US | disclosed |
| US-20210401792-A1 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | Abliva Ab (SE) | 2021-12-30 | — | — | US | disclosed |
| US-11147789-B2 | Cell-permeable succinate compounds | Abliva Ab (SE) | 2021-10-19 | — | — | US | disclosed |
| US-11147789-B2 | Cell-permeable succinate compounds | Abliva Ab (SE) | 2021-10-19 | — | — | US | disclosed |
| US-10307389-B2 | Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to Complex I-related impairment of mitochondrial oxidative phosphorylation | NEUROVIVE PHARMACEUTICAL AB (SE) | 2019-06-04 | — | — | US | disclosed |
| EP-3391941-A1 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | NeuroVive Pharmaceutical AB (SE) | 2018-10-24 | — | — | EP | disclosed |
| EP-3129016-B1 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | NEUROVIVE PHARMACEUTICAL AB (SE) | 2018-06-06 | — | — | EP | disclosed |
| EP-3129016-B1 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | NEUROVIVE PHARMACEUTICAL AB (SE) | 2018-06-06 | — | — | EP | disclosed |
| US-20170105961-A1 | Novel Cell-Permeable Succinate Compounds | Abliva Ab (SE) | 2017-04-20 | — | — | US | disclosed |
| US-20170105961-A1 | Novel Cell-Permeable Succinate Compounds | Abliva Ab (SE) | 2017-04-20 | — | — | US | disclosed |
| US-20170100359-A1 | Succinate Prodrugs for Use in the Treatment of Lactic Acidosis or Drug-Induced Side-Effects Due to Complex I-Related Impairment of Mitochondrial Oxidative Phosphorylation | Abliva Ab (SE) | 2017-04-13 | — | — | US | disclosed |
| US-20170100359-A1 | Succinate Prodrugs for Use in the Treatment of Lactic Acidosis or Drug-Induced Side-Effects Due to Complex I-Related Impairment of Mitochondrial Oxidative Phosphorylation | Abliva Ab (SE) | 2017-04-13 | — | — | US | disclosed |
| EP-3129058-A1 | SUCCINATE PRODRUGS FOR USE IN THE TREATMENT OF LACTIC ACIDOSIS OR DRUG-INDUCED SIDE-EFFECTS DUE TO COMPLEX I-RELATED IMPAIRMENT OF MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION | Neurovive Pharmaceutical AB (SE) | 2017-02-15 | — | — | EP | disclosed |
| EP-3129016-A1 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | Neurovive Pharmaceutical AB (SE) | 2017-02-15 | — | — | EP | disclosed |
| WO-2015155231-A1 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | NEUROVIVE PHARMACEUTICAL AB (SE) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015155238-A1 | SUCCINATE PRODRUGS FOR USE IN THE TREATMENT OF LACTIC ACIDOSIS OR DRUG-INDUCED SIDE-EFFECTS DUE TO COMPLEX I-RELATED IMPAIRMENT OF MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION | NEUROVIVE PHARMACEUTICAL AB (SE) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015155238-A1 | SUCCINATE PRODRUGS FOR USE IN THE TREATMENT OF LACTIC ACIDOSIS OR DRUG-INDUCED SIDE-EFFECTS DUE TO COMPLEX I-RELATED IMPAIRMENT OF MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION | NEUROVIVE PHARMACEUTICAL AB (SE) | 2015-10-15 | — | — | WO | disclosed |
| WO-2015155231-A1 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | NEUROVIVE PHARMACEUTICAL AB (SE) | 2015-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170105961-A1 | Novel Cell-Permeable Succinate Compounds | SLC25A1, SLC25A11, CS | GNPAT 959/4885NOD1 4482/4885FOLH1 1286/4885 |
| US-11147789-B2 | Cell-permeable succinate compounds | SLC25A1, SLC25A11, SLC25A21 | GNPAT 1085/4885NOD1 4463/4885FOLH1 1521/4885 |
| US-20170100359-A1 | Succinate Prodrugs for Use in the Treatment of Lactic Acidosis or Drug-Induced Side-Effects Due to Complex I-Related Impairment of Mitochondrial Oxidative Phosphorylation | CS, MDH2, SLC25A11 | GNPAT 271/4885NOD1 4339/4885FOLH1 690/4885 |
| US-10307389-B2 | Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to Complex I-related impairment of mitochondrial oxidative phosphorylation | CS, MDH2, SLC25A11 | GNPAT 271/4885NOD1 4339/4885FOLH1 690/4885 |
| US-20210401792-A1 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | SLC25A1, SLC25A11, CS | GNPAT 1061/4885NOD1 4463/4885FOLH1 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.